Physician

Abdel Karim Jibawi, M.D.

According to 2025 Medicare claims, Abdel Jibawi, M.D. (NPI: 1912261876) practices family practice in the Homosassa Springs, FL market, with the plurality of this provider's patient population coming from Citrus, FL. This provider's primary affiliated billing organization is ACCESS HEALTH CARE PHYSICIANS LLC (NPI: 1245529742; TIN: 451444883) and primary practice location at 34446-4562. Jibawi is affiliated with the Physicians ACO, LLC (ACO ID: A2551) and Humana Direct Contracting Entity, Inc. (ACO ID: D0203), participating under both the MSSP and REACH models.

Jibawi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 125 traditional Medicare patients, billed 557 HCPCS/CPT codes, and received $21,690 in Medicare payments. The top billing code was G0438 (Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit). Part D data shows 31,267 prescription claims across 2,003 beneficiaries totaling $2,088,413 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 84 claims. Open Payments data shows 43 records totaling $863. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $37,692 and ending at $21,690. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $5,551 to $2,088,413. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $1,430 to $1,912.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	271	583	$37,692
2017	509	1,208	$48,941
2018	470	1,150	$51,113
2019	357	851	$41,536
2020	137	282	$17,062
2021	184	607	$40,379
2022	195	1,081	$41,340
2023	195	1,432	$39,501
2024	125	557	$21,690

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	284	376	$5,551
2016	542	941	$26,293
2017	1,276	5,715	$201,799
2018	1,402	8,487	$364,027
2019	1,398	8,612	$412,891
2020	1,540	7,011	$454,908
2021	1,173	12,382	$929,874
2022	1,960	20,813	$1,435,191
2023	2,123	31,895	$2,368,699
2024	2,003	31,267	$2,088,413

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	26	$99
2018	N/R	57	$878
2019	N/R	74	$1,611
2020	N/R	29	$659
2021	N/R	14	$322
2022	N/R	63	$1,200
2023	N/R	84	$3,441
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0438	Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit	17	17	$160
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	84	159	$83
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	65	107	$13
36415	Insertion of needle into vein for collection of blood sample	92	159	$8
81002	Urinalysis, manual test	15	18	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	287	17,225	$312,756
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	198	8,430	$177,934
Jardiance	Empagliflozin	57	2,960	$63,110
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	16	480	$60,336
Spiriva Respimat	Tiotropium Bromide	76	4,140	$58,501

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	43	$863	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abdel Karim Jibawi, M.D.?

Tedicare shows public-source Medicare data for Abdel Karim Jibawi, M.D. (NPI 1912261876), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abdel Karim Jibawi, M.D. have ACO affiliation data?

Abdel Karim Jibawi, M.D. is shown with ACO affiliation data for Physicians ACO, LLC (MSSP, ACO ID A2551) and Humana Direct Contracting Entity, Inc. (REACH, ACO ID D0203).

What billing organization is linked to Abdel Karim Jibawi, M.D.?

Abdel Karim Jibawi, M.D. is linked to ACCESS HEALTH CARE PHYSICIANS LLC (billing NPI 1245529742) in the available physician profile data.

Does Abdel Karim Jibawi, M.D. have Open Payments data?

Abdel Karim Jibawi, M.D. has 43 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.